Stifel initiates research coverage of Xlife Sciences

Xlife Sciences AG

/ Key word(s): Miscellaneous

Stifel initiates research coverage of Xlife Sciences

23.01.2023 / 07:00 CET/CEST


The renowned investment bank Stifel commenced its research coverage of Xife Sciences (SIX: XLS). The corresponding initial analyst report rates Xlife Sciences’ stock with a “Buy” rating and calls for a price target of CHF 68.00.-

Stifel’s initiation report emphasizes that Xlife Sciences provides investors access to early-stage life science research projects from universities and other institutions. As competition is limited at this stage, the company can choose among the best projects. The report also outlines that Xlife Sciences plans to exit up to four of its portfolio companies in 2023 and ten to eleven in total until year-end 2024; the total targeted value creation of CHF 100-150 million with these planned exits is considered as “meaningful” amount for a small-cap company. The analyst report also takes note of the highly experienced Advisory Board as well as the competent Management Team.

At, a summary of Stifel’s first analyst report on Xlife Sciences can be viewed and downloaded. After Intron Health and Baader Bank, Stifel is the third financial services firm having initiated independent research coverage of Xlife Sciences.

Financial calendar

Annual Report 2022                                   April 20, 2023

AGM 2023                                                  June 20, 2023

Half-Year Report 2023                               September 21, 2023


Information for journalists: IRF Reputation AG, Valentin Handschin,

Information for investors: Xlife Sciences AG, Dennis Lennartz,

Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Phone +41 44 385 84 60,, 
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange

About Xlife Sciences AG (SIX: XLS) 

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit 


Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements. 

End of Media Release

Language: English
Company: Xlife Sciences AG
Talacker 35
8001 Zürich
Phone: +41 44 385 84 60
ISIN: CH0461929603
Valor: A2PK6Z
Listed: SIX Swiss Exchange
EQS News ID: 1540625

End of News EQS News Service

1540625  23.01.2023 CET/CEST

EQS 2023

All news about XLIFE SCIENCES AG

Sales 2022 0,80 M
0,87 M
0,87 M
Net income 2022 -9,00 M
-9,77 M
-9,77 M
Net Debt 2022 62,4 M
67,8 M
67,8 M
P/E ratio 2022 -20,1x
Yield 2022
Capitalization 191 M
208 M
208 M
EV / Sales 2022 317x
EV / Sales 2023 319x
Nbr of Employees 13
Free-Float 45,8%

Duration :

Period :

Xlife Sciences AG Technical Analysis Chart | MarketScreener

Technical analysis trends XLIFE SCIENCES AG

Short Term Mid-Term Long Term
Trends Bullish Bullish Neutral

Income Statement Evolution



Mean consensus BUY
Number of Analysts 1
Last Close Price 35,80 CHF
Average target price 68,00 CHF
Spread / Average Target 89,9%

Leave a Comment